Results 241 to 250 of about 156,017 (326)

The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease

Clinical Pharmacology in Drug Development, EarlyView.
Abstract BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha‐7 nicotinic acetylcholine receptor (α7 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention ...
Paul Rolan, Elizabeth Doolin, Dharam Paul, Julia Crossman, Michael Odontiadis, Philippe Danjou, Mark Smith, Spyros Papapetropoulos   +7 more
wiley   +1 more source

Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial

, 2019
Gabriel Gastaminza, Julián Azofra, Jorge M. Núñez‐Córdoba, M. L. Baeza, S. Echechipía, P Gaig, Blanca E. García, Moisés Labrador‐Horrillo, Anna Sala, Marina Sabaté‐Brescó, Ana Beristain, Diwa Malaya Aldana Quiñones, Carmen Díaz Donado, José Manuel Zubeldia, Marta Ferrer   +14 more
openalex   +2 more sources

Cannabidiol in autism: Clinical pharmacology priorities for trial design

British Journal of Clinical Pharmacology, EarlyView.
Gislei Frota Aragão, Carla Barbosa Brandão, José Evaldo Leandro Júnior   +2 more
wiley   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

A Phase 1 Open‐Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Intranasal Dose of Zavegepant in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Zavegepant is the only calcitonin gene‐related peptide antagonist approved as a nasal spray in the United States for acute treatment of migraine in adults with or without aura. This Phase 1, open‐label study evaluated the pharmacokinetics, safety, and tolerability of a single intranasal dose of zavegepant 10 mg in 12 healthy Chinese adults ...
Qiong Wei, Jufang Wu, Yangyi Dai, Jiaye Lin, Beikang Ge, Yanhui Sun, Jing Zhang, Jing Wang, Chen Li, Ding Ding, Jing Liu, Mohamed H. Shahin   +11 more
wiley   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

Neural and molecular changes during a mind-body reconceptualization, meditation, and open label placebo healing intervention [PDF]

Alex Jinich‐Diamant, Sierra Simpson, Juan Pablo Zuniga-Hertz, Ramamurthy Chitteti, Jan M. Schilling, Jacqueline A. Bonds, Laura K. Case, Andrei V. Chernov, Joe Dispenza, Jacqueline Maree, Neil Stahl, Michael Licamele, Narin Fazlalipour, Swetha Devulapalli, Leonardo Christov‐Moore, Nicco Reggente, Michelle A. Poirier, Tobias Moeller‐Bertram, Hemal H. Patel   +18 more
openalex   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T. Matschke, Richard Bertz, Robert Croop, Jing Liu   +6 more
wiley   +1 more source

Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Since 2016, the China National Medical Products Administration (NMPA) has reformed its drug registration classification rules and defines the innovative drugs as new drugs that have not been marketed domestically and overseas. This study sought to systematically evaluate the characteristics of the innovative drugs approved in China. The cross‐sectional
Xingyue Zhu, Die Xiao
wiley   +1 more source

Clinical effects of cyclosporine A on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials [PDF]

, 2016

core   +1 more source